Cisapride (R 51619): A Nonselective 5-HT4 Receptor Agonist for Cardiac Electrophysiology Research

Executive Summary: Cisapride (R 51619) is a nonselective 5-HT4 receptor agonist and a potent hERG potassium channel inhibitor, enabling detailed study of cardiac electrophysiology and arrhythmia mechanisms (Grafton et al., 2021). The compound is highly soluble in DMSO (≥23.3 mg/mL), but insoluble in water, with optimal storage at -20°C (APExBIO). Cisapride’s cardiac effects have been characterized in high-content phenotypic screens using iPSC-derived cardiomyocytes (Grafton et al., 2021). The B1198 kit from APExBIO is supplied with ≥99.7% purity and full analytical documentation. Cisapride is not suitable for in vivo or clinical use due to its risk of QT prolongation and arrhythmias (Grafton et al., 2021).

Biological Rationale

Cisapride (R 51619) is a research compound primarily used to interrogate 5-HT4 receptor signaling and hERG channel function in vitro (APExBIO). The 5-HT4 receptor is a G protein-coupled receptor (GPCR) that modulates gastrointestinal motility and cardiac conduction (see mechanistic review). hERG potassium channels (encoded by KCNH2) are essential for cardiac repolarization; their inhibition is a well-established cause of drug-induced QT prolongation and arrhythmias (Grafton et al., 2021). Cisapride's dual activity enables researchers to dissect serotonergic and electrophysiological pathways relevant to arrhythmogenesis and drug safety screening.

Mechanism of Action of Cisapride (R 51619)

Cisapride acts as a nonselective 5-HT4 receptor agonist, increasing cAMP production and downstream signaling in cells expressing the receptor (contextual analysis). It also potently inhibits the hERG potassium channel by direct channel blockade, resulting in delayed cardiac repolarization. The inhibition of hERG is concentration-dependent, with half-maximal inhibitory concentration (IC₅₀) values typically in the low micromolar range for human channels. Structurally, Cisapride is classified as 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide, with a molecular weight of 465.95 (APExBIO).

Evidence & Benchmarks

• Cisapride induces marked cardiotoxicity phenotypes in human iPSC-derived cardiomyocytes, as measured by deep learning-based image analysis (Grafton et al., 2021, DOI).
• Cisapride inhibits hERG potassium currents in vitro, with IC₅₀ values reported at 16–30 nM in heterologous systems (Smith et al., 2002, PubMed).
• The compound is highly soluble in DMSO (≥23.3 mg/mL) and ethanol (≥3.47 mg/mL), but insoluble in water (APExBIO, product documentation).
• Cisapride-induced QT prolongation and ventricular arrhythmias have been confirmed in both preclinical and clinical reports, leading to its withdrawal from many markets (Redfern et al., 2003, DOI).
• High-content iPSC-CM screening platforms efficiently detect Cisapride-induced electrophysiological changes, supporting its use as a benchmark tool in predictive toxicology (Grafton et al., 2021, DOI).

Applications, Limits & Misconceptions

Cisapride is used in vitro to:

• Model drug-induced QT prolongation and arrhythmia in iPSC-derived cardiomyocytes.
• Characterize 5-HT4 receptor signaling in gastrointestinal and cardiac assays.
• Serve as a positive control for hERG channel inhibition in safety pharmacology screens.
• Benchmark high-throughput phenotypic assays in cardiac electrophysiology research (see systems-biology perspective—this article expands on AI-driven integration compared to prior reports).

Common Pitfalls or Misconceptions

• Not for in vivo/clinical use: Cisapride is unsuitable for human or animal administration due to arrhythmia risk.
• Water insolubility: It cannot be used in aqueous buffer systems without cosolvents (e.g., DMSO).
• hERG selectivity: Cisapride is nonselective and may affect other cardiac ion channels at higher concentrations.
• Gastrointestinal vs. cardiac effects: In vitro data do not predict gastrointestinal efficacy or side effect profiles in vivo.
• Long-term solution instability: Solutions degrade over time, even at -20°C; freshly prepare before use.

Workflow Integration & Parameters

APExBIO supplies Cisapride (R 51619) as SKU B1198 with ≥99.7% purity, validated by HPLC, NMR, and MSDS documentation (product page). For in vitro use, dissolve in DMSO to desired concentration (e.g., 10 mM stock); further dilute into assay buffer ensuring final DMSO concentration does not exceed cellular tolerance (typically ≤0.1%). Store solid at -20°C; avoid repeated freeze-thaw cycles. For cardiac electrophysiology studies, use in parallel with iPSC-derived cardiomyocytes to benchmark drug-induced arrhythmogenicity (extended discussion—this article details integration with iPSC-CM models beyond prior summaries).

Conclusion & Outlook

Cisapride (R 51619) remains a reference 5-HT4 receptor agonist and hERG inhibitor for in vitro cardiac electrophysiology and toxicology research. Its robust solubility and analytical profile make it a preferred positive control in high-throughput and phenotypic screening platforms. While its use is limited to research settings due to arrhythmogenic risk, APExBIO’s B1198 kit provides a stable, high-purity reagent for reproducible results. Ongoing developments in iPSC models and AI-driven screening are further extending Cisapride’s utility in preclinical safety and mechanistic studies (see advanced assay design—this article provides updated parameters for integration and translational use).